NCT00964132View on ClinicalTrials.gov

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

PHASE2UnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

June 30, 2010

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

NRX194204

Once Daily, Oral

Trial Locations (6)

90033

USC Norris Comprehensive Cancer Center, Los Angeles

92708

Dr. Pandit, Fountain Valley

98104

Swedish Cancer Institute, Seattle

92093-0698

UCSD Moores Cancer Center, La Jolla

03756

Dartmouth Hitchcock Medical Center, Lebanon

08876

Somerset Oncology Hematology Associates, Somerville

Sponsors
All Listed Sponsors
lead

NuRx Pharmaceuticals, Inc.

INDUSTRY

NCT00964132 - Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter